Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome

References

• Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–421.
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010;2(3):180–93.
   PubMed Web of Science ®Google Scholar
• Yubero-Serrano EM, Delgado-Lista J, Pena-Orihuela P, Perez-Martinez P, Fuentes F, Marin C, et al. Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study. Exp Mol Med 2013;45:e28.
   PubMedGoogle Scholar
• Kontush A, Chapman MJ. Antiatherogenic small, dense HDL – guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006;3(3):144–53.
   PubMedGoogle Scholar
• Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104(1–2):129–35.
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101(8):1581–90.
   PubMed Web of Science ®Google Scholar
• Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004;4(4):211–7.
   PubMedGoogle Scholar
• Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 2002;277(6):4301–8.
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37(9):1304–16.
   PubMed Web of Science ®Google Scholar
• Precourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011;214(1):20–36.
   PubMed Web of Science ®Google Scholar
• Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007;39(8):1423–34.
   PubMed Web of Science ®Google Scholar
• Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alderson NL, DuBose KD. Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. Sports Med 2001;31(15):1033–62.
   PubMed Web of Science ®Google Scholar
• Grandjean PW, Crouse SF, Rohack JJ. Influence of cholesterol status on blood lipid and lipoprotein enzyme responses to aerobic exercise. J Appl Physiol 2000;89(2):472–80.
   PubMed Web of Science ®Google Scholar
• Crouse SF, O'Brien BC, Rohack JJ, Lowe RC, Green JS, Tolson H, et al. Changes in serum lipids and apolipoproteins after exercise in men with high cholesterol: influence of intensity. J Appl Physiol 1995;79(1):279–86.
   PubMed Web of Science ®Google Scholar
• Tomas M, Elosua R, Senti M, Molina L, Vila J, Anglada R, et al. Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonase1 activity. J Lipid Res 2002;43(5):713–20.
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Lewandowski M, Stolarek R, Szkudlarek U, Nowak D, Orlowska-Majdak M. Effect of single bout of maximal exercise on plasma antioxidant status and paraoxonase activity in young sportsmen. Redox Rep 2010;15(6):275–81.
   PubMed Web of Science ®Google Scholar
• Vollaard NB, Shearman JP, Cooper CE. Exercise-induced oxidative stress: myths, realities and physiological relevance. Sports Med 2005;35(12):1045–62.
   PubMed Web of Science ®Google Scholar
• Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;101(21):2510–7.
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26(7–8):892–904.
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82(12A):74U–81U; discussion 5U–6U.
   PubMed Web of Science ®Google Scholar
• Goldberg A, Alagona P Jr, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85(9):1100–5.
   PubMed Web of Science ®Google Scholar
• Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 2004;107(5):435–47.
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Nyaku M, Horvath KV, et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008;28(9):1672–8.
   PubMed Web of Science ®Google Scholar
• Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010;121(1):110–22.
   PubMed Web of Science ®Google Scholar
• Plaisance EP, Mestek ML, Mahurin AJ, Taylor JK, Moncada-Jimenez J, Grandjean PW. Postprandial triglyceride responses to aerobic exercise and extended-release niacin. Am J Clin Nutr 2008;88(1):30–7.
   PubMed Web of Science ®Google Scholar
• Otvos JD, Jeyarajah EJ, Bennett DW. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem 1991;37(3):377–86.
   PubMed Web of Science ®Google Scholar
• Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992;38(9):1632–8.
   PubMed Web of Science ®Google Scholar
• Benitez S, Sanchez-Quesada JL, Lucero L, Arcelus R, Ribas V, Jorba O, et al. Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are related to the increase in associated non-esterified fatty acids. Atherosclerosis 2002;160(1):223–32.
   PubMed Web of Science ®Google Scholar
• Iborra RT, Ribeiro IC, Neves MQ, Charf AM, Lottenberg SA, Negrao CE, et al. Aerobic exercise training improves the role of high-density lipoprotein antioxidant and reduces plasma lipid peroxidation in type 2 diabetes mellitus. Scand J Med Sci Sports 2008;18(6):742–50.
   PubMed Web of Science ®Google Scholar
• Cakmak A, Zeyrek D, Atas A, Erel O. Paraoxonase activity in athletic adolescents. Pediatr Exerc Sci 2010;22(1):93–104.
   PubMed Web of Science ®Google Scholar
• Hamurcu Z, Saritas N, Baskol G, Akpinar N. Effect of wrestling exercise on oxidative DNA damage, nitric oxide level and paraoxonase activity in adolescent boys. Pediatr Exerc Sci 2010;22(1):60–8.
   PubMed Web of Science ®Google Scholar
• Bergmeier C, Siekmeier R, Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 2004;50(12):2309–15.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162(14):1568–76.
   PubMedGoogle Scholar
• Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelstiel CD, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006;98(6):743–5.
   PubMed Web of Science ®Google Scholar
• Jafri H, Alsheikh-Ali AA, Mooney P, Kimmelstiel CD, Karas RH, Kuvin JT. Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD. J Clin Lipidol 2009;3(1):45–50.
   PubMed Web of Science ®Google Scholar
• Shearer GC, Pottala JV, Hansen SN, Brandenburg V, Harris WS. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. J Lipid Res 2012;53(11):2429–35.
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000;2(1):36–46.
   PubMedGoogle Scholar